Your session is about to expire
← Back to Search
Open Label Enstilar for Psoriasis
Phase 4
Recruiting
Research Sponsored by Psoriasis Treatment Center of Central New Jersey
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 16 weeks
Awards & highlights
Study Summary
4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 16 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~16 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
PGA x BSA improvement
Secondary outcome measures
BSA improvement
Dermatology Life Quality Index improvement
Itch Numerical Rating Scale
Trial Design
1Treatment groups
Experimental Treatment
Group I: Open Label EnstilarExperimental Treatment1 Intervention
once daily for 4 weeks followed by QOD for 12 weeks for patients receiving Enbrel or Humira
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Betamethasone
FDA approved
Find a Location
Who is running the clinical trial?
Psoriasis Treatment Center of Central New JerseyLead Sponsor
14 Previous Clinical Trials
412 Total Patients Enrolled
13 Trials studying Psoriasis
372 Patients Enrolled for Psoriasis
LEO PharmaIndustry Sponsor
268 Previous Clinical Trials
188,421 Total Patients Enrolled
86 Trials studying Psoriasis
33,201 Patients Enrolled for Psoriasis
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger